Vaborbactam (formerly RPX7009) is a member of a new class of β-lactamase inhibitor with
pharmacokinetic properties similar to those of many β-lactams, including carbapenems. The …

β-Lactamases of Ambler's Class A are the most commonly encountered mechanism of
bacterial resistance to β-lactam antibiotics. In the face of selective pressure arising from use …

While β-lactam antibiotics remain among the most commonly prescribed pharmaceutical
products, their effectiveness is currently threatened by the development of bacterial …

The common practice in antibacterial drug development has been to rapidly make an
attempt to find ever-more stable and broad-spectrum variants for a particular antibiotic, once …

Abstract β-Lactamases, major determinants of bacterial resistance to β-lactam antibiotics,
can be classified into specific molecular classes following identification of active-site amino …

The use of β-lactamase inhibitors in combination with β-lactam antibiotics is currently the
most successful strategy to combat a specific resistance mechanism. Their broad spectrum …

Despite major advances in the β-lactamase inhibitor field, certain enzymes remain refractory
to inhibition by agents recently introduced. Most important among these are the class B …

Extended‐spectrum β‐lactamases (ESBLs) are extremely broad spectrum β‐lactamase
enzymes found in a variety of Enterobacteriaceae. Most strains producing these β …

β-lactamases of Gram-negative bacteria are evolving dynamically. New developments
include the production of enzymes with novel substrate profiles, reduced susceptibility to β …

The bicyclic boronate VNRX-5133 (taniborbactam) is a new type of β-lactamase inhibitor in
clinical development. We report that VNRX-5133 inhibits serine-β-lactamases (SBLs) and …